论文部分内容阅读
摘要目的 :评估氟他胺 (Drogenil)作为纯雄激素受体阻滞剂是否可改善胰腺癌患者的预后及睾酮是否为此类肿瘤的生长因子。设计 :前瞻性、随机性、双盲、安慰剂对照研究。对象 :4 9例临床诊断为胰腺癌的患者。方法 :2 4例患者接受氟他胺治疗 ,余 2 5例接受安慰剂。主要观察指标 :患者的生存期。结果 :对所有患者的分析表明 ,氟他胺组 6个月及 1年后仍存活者分别为 14例及 8例 ,安慰剂组分别为 10例及 1例 ,排除两组中因病情恶化或早期死亡而上述治疗少于 6周的患者后 ,氟他胺组存活者分别为 14例 ( 88% )及 8例 ( 5 0 % ) ,安慰剂组分别为 10例 ( 5 0 % )及 1例 ( 5 % )。氟他胺组所有患者的平均生存期为 8个月 ,安慰剂组为 4个月。排除治疗少于 6周的患者后 ,两组平均生存期分别为 12个月及 5个月。结论 :本研究支持睾酮是胰腺癌生长因子的观点 ,阻断雄激素受体可提供适于胰腺癌治疗的新途径
ABSTRACT Objective: To evaluate whether Fluo-Dilgenil as a pure androgen receptor blocker can improve the prognosis of patients with pancreatic cancer and whether testosterone is a growth factor for such tumors. Design: Prospective, randomized, double-blind, placebo-controlled study. Subjects: 49 patients with clinically diagnosed pancreatic cancer. Methods: Twenty-four patients received flutamide treatment and the remaining 25 received placebo. MAIN OUTCOME MEASURES: The patient’s survival period. Results: Analysis of all patients showed that in the flutamide group, 14 and 8 survivors were still alive after 6 months and 1 year respectively, and 10 and 1 were in the placebo group, respectively. In patients who died early after treatment for less than 6 weeks, 14 (88%) and 8 (50%) survivors were in the flutamide group, and 10 (50%) and 1 in the placebo group, respectively. Example (5%). The average survival time of all patients in the flutamide group was 8 months, and that of the placebo group was 4 months. After excluding patients treated for less than 6 weeks, the average survival time for the two groups was 12 months and 5 months, respectively. Conclusion: This study supports the view that testosterone is a growth factor for pancreatic cancer. Blocking androgen receptor can provide a new approach for the treatment of pancreatic cancer.